Skip to main content

Table 4 Toxicity per cycle and per patient

From: Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience

Toxicity

Per cycle (n = 169)

Per patient (n = 33)

Hematological

Grade 2

Grade 3

Grade 4

Grade 2

Grade 3

Grade 4

 

No. (%)

No. (%)

No. (%)

No. (%)

No. (%)

No. (%)

Leucopenia

51 (30)

31 (18)

9 (5)

11 (33)

6 (18)

8 (24)

Neutropenia

11 (6)

22 (13)

60 (36)

2 (6)

5 (15)

18 (54)

Thrombocytopenia

12 (7)

4 (2)

0

5 (15)

4 (12)

0

Anemia

26 (15)

5 (3)

0

12 (36)

2 (6)

0

Non hematological

      
 

No. (%)

No. (%)

No. (%)

No. (%)

No. (%)

No. (%)

Nausea/vomiting

14 (9)

2 (1)

0

9 (27)

1 (3)

0 (0)

Diarrhea

8 (5)

1 (1)

1 (1)

7 (21)

1 (3)

1 (3)

Stomatitis

14 (8)

1 (1)

0

7 (21)

1 (3)

0

Neurosensory

14 (8)

0

0

6 (18)

0

0

Fever

16 (9)

0

0

8 (24)

0

0

Infection

2 (1)

0

0

1 (3)

0

0

Thromboembolism

2 (1)

0

0

2 (6)

0

0

Hypersensitivity

1 (1)

0

0

1 (3)

0

0